Dr. David Binder, MD

Dr. Binder practices at UCHealth University of Colorado Hospital in Aurora, Colorado, part of UCHealth.

Dr. Binder's NPI, 1629463153, was assigned on April 1, 2015. Dr. Binder graduated from University of Chicago, Pritzker School of Medicine in 2015. Dr. Binder holds Colorado license DR.0068983.

Dr. Binder's primary practice is UCHealth University of Colorado Hospital, at 12605 E 16th Ave, Aurora, CO 80045 in Adams County. The practice phone is (720) 848-0000.

Dr. Binder's primary practice is UCHealth University of Colorado Hospital in Aurora, Colorado, part of UCHealth. Dr. Binder is also affiliated with UCHealth Highlands Ranch Hospital. The medical group on file is University of Colorado Medicine (CU Medicine). Dmand AI also links Dr. Binder to 2 more hospitals, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Binder practices, 5 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Binder's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dmand AI has Dr. Binder's licenses on file in 2 states: Colorado and Missouri.

CMS data shows 1,340 Medicare services from Dr. Binder across 18 procedure codes in 2024, for 348 Medicare patients. Medicare paid $103,655 for them.

CMS counts 348 Medicare patients who saw Dr. Binder in 2024. The largest group is 65 to 74, with 181 patients. 71% of them have cancer, and 71% have high blood pressure. 15% are also on Medicaid. Their average risk score is 1.92, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Binder's median patient age at 71, with 50% women.

In 2024, Dr. Binder wrote 129 Medicare Part D claims for 67 patients. 86% of them were for generic drugs. CMS names the drug for 63 of them, across 3 drugs with 11 or more claims each, at $1,014 in total drug cost. In 2023, CMS named 59 claims across 4 drugs.

Dr. Binder accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Binder as offering telehealth.

Dmand AI links 23 papers to Dr. Binder, published from 2012 to 2018. 2017 was the busiest year, with 5. The most frequent topics are Cell Line, Tumor, Glioblastoma and Indoleamine-Pyrrole 2,3,-Dioxygenase. Dr. Binder has published most often in Oncoimmunology. Dr. Binder's most frequent co-authors are Sana Dole Karam, MD, Alicia Campbell Lenzen, MD and Rimas Vincas Lukas, MD.

Dmand AI links Dr. Binder to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Carcinoma, Intraductal, Noninfiltrating and Breast Carcinoma In Situ.

CMS Open Payments shows 9 general payments to Dr. Binder from 6 drug and device companies from 2020 to 2023. Food and beverage make up the largest share, 54% of the total. AstraZeneca Pharmaceuticals LP paid the most, $228.

Dr. Binder graduated from University of Chicago, Pritzker School of Medicine in 2015.